Bristol Myers Squibb stock holds near analyst targets as 2026 guidance firms up
Published on 09/12/2026 at 14:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) closed at USD 63.64 on the New York Stock Exchange on September 11, 2026, leaving the shares trading slightly below a consensus analyst price target of USD 66.33 and aligned with full-year 2026 earnings guidance of USD 6.75 to USD 7.00 per share.
Analyst targets cluster just above the current price
Analyst views on Bristol Myers Squibb have converged around a moderate upside scenario in early September 2026, with the average price target only a small step above the latest close. According to MarketBeat on September 12, 2026, Bristol Myers Squibb carries a Moderate Buy consensus rating, with an average target of USD 66.33 based on one strong buy, thirteen buy, ten hold and one sell recommendation, implying about 4.2 percent potential upside versus the September 11, 2026 closing price of USD 63.64.
The same overview from MarketBeat notes that Bristol Myers Squibb stock opened at USD 63.52 on September 12, 2026, after that prior close, with the consensus target essentially sitting within the upper part of the 52-week trading range, which has recently stretched between roughly the low-40s and the high-60s in USD terms.
2026 guidance and Q2 figures underpin the valuation
Fundamentals give context to why the analyst targets are relatively close to the current share price. According to StockTitan on September 12, 2026, Bristol Myers Squibb reported Q2 2026 revenues of USD 12,973 million, a 6 percent increase year over year, while net earnings attributable to the company rose to USD 3,317 million from the prior-year quarter.
In the same Q2 2026 update, GAAP diluted earnings per share climbed to USD 1.62 from USD 0.64 a year earlier, and non-GAAP diluted EPS increased to USD 2.04 from USD 1.46, showing that adjusted earnings advanced by about 39.7 percent compared with the prior-year quarter, even as legacy products faced generic competition, according to StockTitan.
Bristol Myers Squibb has also issued full-year 2026 guidance that helps frame the analyst estimates. As summarized by MarketBeat on September 12, 2026, Bristol Myers Squibb has set its fiscal year 2026 earnings guidance at USD 6.75 to USD 7.00 per share, while the average analyst forecast stands at around USD 6.95 per share for the same period, placing the midpoint of management guidance slightly above consensus and indicating confidence in the earnings trajectory.
Growth and legacy portfolios move in different directions
The composition of revenue growth is another element investors monitor. According to the Q2 2026 figures highlighted by StockTitan, Bristol Myers Squibb's Growth Portfolio generated USD 7,560 million in revenue in Q2 2026, up 15 percent year over year, supported by oncology and cardiovascular products such as Reblozyl, Breyanzi, Camzyos, Opdualag and Opdivo Qvantig.
By contrast, the Legacy Portfolio declined 4 percent to USD 5,422 million in Q2 2026, as strong growth in Eliquis revenue to USD 4,481 million, representing a 22 percent increase year over year, was more than offset by sharp generic-driven declines in Revlimid and Pomalyst/Imnovid, according to StockTitan.
Pipeline and regulatory pressures shape the risk profile
Beyond current numbers, pipeline progress and policy risks influence how closely the stock trades to analyst targets. On the growth side, Bristol Myers highlighted in its recent communications that it is advancing a broad pipeline and has entered a major collaboration with Hengrui for 13 early-stage assets, according to StockTitan, which investors may see as support for longer-term revenue diversification.
At the same time, the company has flagged U.S. Inflation Reduction Act "maximum fair price" decisions on key drugs such as Eliquis and Pomalyst, as well as upcoming negotiations around Orencia, as potential headwinds that could exert pressure on future revenue, according to StockTitan, making policy outcomes an important risk factor to watch.
Stock trades in the upper third of its 52-week range
The recent share-price pattern mirrors the mixed picture of growth and pressure points. Price data compiled by Forbes show that Bristol Myers Squibb stock closed at USD 63.64 on September 11, 2026, after ending at USD 63.75 on September 10, 2026, and trading between an intraday high of USD 64.20 and a low of USD 63.27 on September 11, 2026, with volume of 699,113 shares.
Over the past 52 weeks, Bristol Myers Squibb shares have moved between a low near USD 42.52 and a high around USD 68.64, and with the September 11, 2026 closing price of USD 63.64, the stock currently trades in the upper third of that range, roughly USD 21.12 above the low and about USD 5.00 below the high, a position that reflects both solid earnings trends and the limited quantified upside implied by the consensus target.
Key data on Bristol Myers Squibb stock
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 11, 2026, 16:00): 63.64 USD
- Market capitalization: 128,000,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
